Skip to main content

KROS research · 13F holders by reporting quarter

Keros Therapeutics, Inc. (KROS): 13F holders, 2026Q2

The largest share positions in KROS that the managers Kresmion follows reported on Form 13F for 2026Q2, as filed. The current quarter, the company's SEC filings and its recent events are on the KROS research page.

KROS positions held by the managers we follow (2026Q2)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
CITADEL ADVISORS LLC FundCUSIP 492327101 · 2026Q2$4.2M0.00%
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 492327101 · 2026Q2$3.8M0.01%
D. E. Shaw & Co., Inc. FundCUSIP 492327101 · 2026Q2$2.9M0.00%
TWO SIGMA INVESTMENTS, LP FundCUSIP 492327101 · 2026Q2$2.6M0.00%
MILLENNIUM MANAGEMENT LLC FundCUSIP 492327101 · 2026Q2$2M0.00%
Point72 Asset Management, L.P. FundCUSIP 492327101 · 2026Q2$111K0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.